Table 2.
The proportion of different RADs in COVID-19 infection.
| Author | Country | N | RA (%) | SpA (%) | CTD (SLE included) (%) | PsA (%) | Vasculitis (%) | Polymyalgia rheumatica (%) | SS (%) | Miscellaneous (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Nuño et al. | Spain | 122 | 33.6 | 19.7 | 10.7 | 10.7 | NA | NA | NA | 25.4 |
| Freites Nuñez et al. | Spain | 123 | 40.65 | 14.63 | 6.5 | 4.88 | 1.63 | NA | 7.32 | 4.88 |
| Scirè et al. | Italy | 232 | 34.1 | 26.3 | 21.1 | NA | 11.2 | NA | NA | NA |
| Tan et al. | UK | 133,589 | 3.9–18.9 | NA | NA | 3.5–32.5 | 3.3–17.6 | 4.88 | NA | NA |
| Montero et al. | Spain | 62 | 32 | 26 | 36 | NA | NA | NA | NA | NA |
| Galarza-Delgado et al. | Mexico | 38 | 39.47 | 8.5 | 34.21 | 6.9 | NA | NA | NA | NA |
| Gianfrancesco et al. | Australia | 600 | 38 | 8 | 14 | 12 | 7 | 2 | 5 | 5 |
RADs, rheumatic autoimmune diseases; N, patients with rheumatic immune diseases with COVID-19; RA, rheumatoid arthritis; SpA, spondyloarthritis; CTD, connective tissue diseases; SLE, systemic lupus erythematosus; PsA, psoriatic arthritis; SS, Sjogren Syndrome; NA, data not avaliable.